Alexandra Simbrich1, Ina Wellmann1, Jan Heidrich2, Oliver Heidinger2, Hans-Werner Hense3. 1. Institute of Epidemiology and Social Medicine, University of Münster, Germany. 2. Epidemiological Cancer Registry North Rhine-Westphalia, Münster, Germany. 3. Institute of Epidemiology and Social Medicine, University of Münster, Germany; Epidemiological Cancer Registry North Rhine-Westphalia, Münster, Germany. Electronic address: hense@uni-muenster.de.
Abstract
BACKGROUND: Mammography screening programs (MSPs) aim to detect early-stage breast cancers in order to decrease the incidence of advanced-stage breast cancers and to reduce breast cancer mortality. We analyzed the time trends of advanced-stage breast cancer incidence rates in the target population before and after implementation of the MSP in a region of northwestern Germany. METHODS: The MSP in the Münster district started in October 2005. A total of 13,874 women with an incident invasive breast cancer (BC) was identified by the population-based epidemiological cancer registry between 2000 and 2013 in the target group 50-69 years. Multiple imputation methods were used to replace missing data on tumor stages (10.4%). The incidence rates for early-stage (UICC I) and advanced-stage (UICC II+) BC were determined, and Poisson regression analyses were performed to assess trends over time. RESULTS: The incidence rates for UICC I breast cancers increased during the step-up introduction of the MSP and remained elevated thereafter. By contrast, after increasing from 2006 to 2008, the incidence rates of UICC II+ breast cancers decreased to levels below the pre-screening period. Significantly decreasing UICC II+ incidence rates were limited to the age group 55-69 years and reached levels that were significantly lower than incidence rates in the pre-screening period. DISCUSSION: The incidence rates of advanced-stage breast cancers decreased in the age groups from 55 years to the upper age limit for screening eligibility, but not in the adjacent age groups. The findings are consistent with MSP lead time effects and seem to indicate that the MSP lowers advanced-stage breast cancer rates in the target population.
BACKGROUND: Mammography screening programs (MSPs) aim to detect early-stage breast cancers in order to decrease the incidence of advanced-stage breast cancers and to reduce breast cancer mortality. We analyzed the time trends of advanced-stage breast cancer incidence rates in the target population before and after implementation of the MSP in a region of northwestern Germany. METHODS: The MSP in the Münster district started in October 2005. A total of 13,874 women with an incident invasive breast cancer (BC) was identified by the population-based epidemiological cancer registry between 2000 and 2013 in the target group 50-69 years. Multiple imputation methods were used to replace missing data on tumor stages (10.4%). The incidence rates for early-stage (UICC I) and advanced-stage (UICC II+) BC were determined, and Poisson regression analyses were performed to assess trends over time. RESULTS: The incidence rates for UICC I breast cancers increased during the step-up introduction of the MSP and remained elevated thereafter. By contrast, after increasing from 2006 to 2008, the incidence rates of UICC II+ breast cancers decreased to levels below the pre-screening period. Significantly decreasing UICC II+ incidence rates were limited to the age group 55-69 years and reached levels that were significantly lower than incidence rates in the pre-screening period. DISCUSSION: The incidence rates of advanced-stage breast cancers decreased in the age groups from 55 years to the upper age limit for screening eligibility, but not in the adjacent age groups. The findings are consistent with MSP lead time effects and seem to indicate that the MSP lowers advanced-stage breast cancer rates in the target population.
Authors: Friedrich Kühn; Charlotte Emmi Elisabeth Simon; Ilhamiyya Aliyeva; Julia KUßMAUL; Jessica GROß; Oliver Schweizerhof; Jens-Uwe Blohmer; Maria Margarete Karsten Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: Pietro Trocchi; Oliver Kuss; Vanessa Kääb-Sanyal; Oliver Heidinger; Andreas Stang Journal: Eur J Epidemiol Date: 2019-10-24 Impact factor: 8.082
Authors: M J M Broeders; P Allgood; S W Duffy; S Hofvind; I D Nagtegaal; E Paci; S M Moss; L Bucchi Journal: BMC Cancer Date: 2018-09-03 Impact factor: 4.430